Ulcerative Colitis Clinical Trial
Official title:
Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection- a Double Blind Randomised Controlled Trial
Verified date | January 2020 |
Source | Oxford University Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Laparoscopic (key-hole) large bowel resection is a minimally invasive procedure when compared
to open large bowel resection, but is still associated with a significant amount of pain and
discomfort. Analgesia is commonly provided by a multi-modal technique involving varying
combinations of paracetamol, Non steroidal anti-inflammatory drugs (NSAIDs), regional
analgesia and oral or parenteral opioids. While epidural analgesia is considered the gold
standard for open colo-rectal procedures it can be associated with significant complications
and may delay hospital discharge in laparoscopic procedures. Opioids are associated with an
increased incidence of nausea, vomiting and sedation and reduced bowel motility which can
also prolong recovery.
Transversus Abdominis Plane (TAP) block is a technique which numbs the nerves carrying pain
sensation from the abdominal wall and provides effective and safe analgesia with minimal
systemic side effects. Their perceived benefits are thought to relate to reduced opioid
consumption and therefore reduced opioid side effects. The investigators believe ultrasound
guided TAP blocks will reduce pain and morphine consumption with a resultant improved patient
satisfaction, earlier return of bowel function and earlier hospital discharge.
The key research question the investigators are trying to answer is whether TAP block provide
better pain relief than local anaesthetic infiltration of the laparoscopic port sites. Both
techniques are currently being used in our hospital and a retrospective audit demonstrated
better analgesia and lower consumption of morphine in the TAP block group.The differences
were not statistically significant as the number patients in the audit were not large
enough.The investigators are hoping that this study will demonstrate that the difference is
real by recruiting the necessary number of patients into each group (36 per group)
Status | Completed |
Enrollment | 72 |
Est. completion date | December 2015 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study. - Male or Female, aged 18 years or above. - Undergoing elective laparoscopic high anterior resection without stoma or laparoscopic right hemicolectomy. - American Society of Anaesthetists physical status (ASA) 1-3 Exclusion Criteria: - Opioid tolerance - Chronic abdominal pain - Allergy/Intolerance: Morphine, local anaesthetics - BMI>35 Kg/M2 - Previous major abdominal surgery - High likelihood of conversion to open procedure - Patients unable to communicate in written and spoken English - Weight less than 50 kg |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Churchill Hospital, Oxford Radcliffe Hospitals NHS trust | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
Oxford University Hospitals NHS Trust |
United Kingdom,
El-Dawlatly AA, Turkistani A, Kettner SC, Machata AM, Delvi MB, Thallaj A, Kapral S, Marhofer P. Ultrasound-guided transversus abdominis plane block: description of a new technique and comparison with conventional systemic analgesia during laparoscopic cholecystectomy. Br J Anaesth. 2009 Jun;102(6):763-7. doi: 10.1093/bja/aep067. Epub 2009 Apr 17. Erratum in: Br J Anaesth. 2009 Oct;103(4):622. — View Citation
McDonnell JG, O'Donnell B, Curley G, Heffernan A, Power C, Laffey JG. The analgesic efficacy of transversus abdominis plane block after abdominal surgery: a prospective randomized controlled trial. Anesth Analg. 2007 Jan;104(1):193-7. Erratum in: Anesth Analg. 2007 May;104(5):1108. — View Citation
McDonnell JG, O'Donnell BD, Farrell T, Gough N, Tuite D, Power C, Laffey JG. Transversus abdominis plane block: a cadaveric and radiological evaluation. Reg Anesth Pain Med. 2007 Sep-Oct;32(5):399-404. — View Citation
Zafar N, Davies R, Greenslade GL, Dixon AR. The evolution of analgesia in an 'accelerated' recovery programme for resectional laparoscopic colorectal surgery with anastomosis. Colorectal Dis. 2010 Feb;12(2):119-24. doi: 10.1111/j.1463-1318.2009.01768.x. Epub 2009 Jan 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Morphine Consumption in the First 48hours After the Operation | Total morphine consumption in the first 48 hours after the surgery will be calculated from the drug chart and the Patient controlled analgesia(PCA)pump. | 48 hours after the operation | |
Secondary | Numerical Rating Pain Scores at 48 Hours Postoperatively | Numerical Rating Scores for Pain (0-10) 0= no pain 10= severe pain | 48 hours after the operation | |
Secondary | Nausea Score at 48 Hours Postoperatively | 0-10 0= no nausea 10=severe nausea | 48 hours after the operation | |
Secondary | Time to First Request for Rescue Analgesia | The time will be calculated from the drug chart looking up when the first dose of rescue morphine was administered | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Time to Mobilisation | Time will be calculated from the nursing notes and patient diary, when the patient was first mobilised. | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Time to Successful Intake of Fluids | Time will be calculated from the nursing notes and patient diary, when the patient had first successful intake of oral fluids. | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Time to Resumption of Normal Diet | Time will be calculated from the nursing notes and patient diary, when the patient resumed normal diet. | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Time to First Bowel Motion | Time will be calculated from the nursing notes and patient diary, when the patient had the first bowel motion. | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Time to First Flatus | Time will be calculated from the nursing notes and patient diary, when the patient first passed flatus. | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Time to Medically Fit to Discharge | Time will be calculated from the medical notes, when the decision that the patient is medically fit to be discharged was made. | After the operation patients will be followed up till they are medically fit to be discharged from the hospital an expected average of 5-7 days. | |
Secondary | Total Morphine Consumption at 24hours | 24 hours | ||
Secondary | Nausea at 24hours Post Operatively | 24 hours | ||
Secondary | Time to Mobilization | days | ||
Secondary | Time to Hospital Discharge | days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |